SELLAS Life Sciences Group Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
SLS$8.58+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share and per share data)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $18,415 | $2,530 |
| Restricted cash and cash equivalents | 100 | 100 |
| Prepaid expenses and other current assets | 2,986 | 542 |
| Total current assets | 21,501 | 3,172 |
| Operating lease right-of-use assets | 747 | 858 |
| Goodwill | 1,914 | 1,914 |
| Deposits and other assets | 272 | 275 |
| Total assets | $24,434 | $6,219 |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $7,407 | $5,639 |
| Accrued expenses and other current liabilities | 6,542 | 7,650 |
| Operating lease liabilities | 488 | 446 |
| Total current liabilities | 14,437 | 13,735 |
| Operating lease liabilities, non-current | 313 | 460 |
| Total liabilities | 14,750 | 14,195 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ (deficit) equity: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 350,000,000 shares authorized, 56,267,670 and 32,132,890 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 5 | 3 |
| Additional paid-in capital | 236,489 | 209,265 |
| Accumulated deficit | (226,810) | (217,244) |
| Total stockholders’ equity (deficit) | 9,684 | (7,976) |
| Total liabilities and stockholders’ equity (deficit) | $24,434 | $6,219 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.